| Therapeutic Translational Research Projects | University of Southern California | PRPE-SF, polarized hESC-derived RPE Soluble Factors, as a Therapy for Early Stage Dry Age-related Macular Degeneration |
$3,697,935 |
| Disease Team Planning | University of Southern California | Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$3,088 |
| Disease Team Therapy Development III | University of Southern California | Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration |
$16,339,827 |
| Disease Team Research I | University of Southern California | Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
